Skip to content

Evaluation of Bioness Integrated Therapy System (BITS) Touch Screen Technology to Improve Field Awareness

Does Bioness Integrated Therapy System (BITS) Touch Screen Technology Improve Field Awareness to Inpatients With Neurological Visual Field Deficits

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04930822
Enrollment
37
Registered
2021-06-18
Start date
2021-01-08
Completion date
2024-09-23
Last updated
2025-12-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acquired Brain Injury, Neurologic Disorder, Stroke, Traumatic Brain Injury

Keywords

Visual Field Cut, Visual Field Interventions, Visual Field Impairments, Hemianopsia, Quadrantanopia, Long Term Acute Care Hospital, Occupational Therapy, Activities of Daily Living, Visual Neglect, Visual Inattention, Hemi-inattention, Touch Screen Technology, Visual Scanning

Brief summary

The Bioness Integrated Therapy System (BITS) (Bioness Inc. Valencia, CA) Touch Screen is an FDA approved device comprised of an interactive touchscreen and diverse program options to challenge patients through the use of visual motor activities, visual and auditory processing, cognitive skills, and endurance training. The purpose of this study is to enroll a small group of adults currently undergoing inpatient rehabilitation, who were admitted for an acute neurological event and present with an acute neurological visual field impairment. The primary objective is to compare any increase in visual field awareness using a prescribed regimen consisting of conventional vision exercises compared with a regimen using BITS touch screen technology. Participants will be alternately assigned into A and B groups upon enrollment. The control group A will be prescribed conventional (table top, pen and paper) vision interventions provided by an occupational therapist and will receive pre- and post- assessment of visual field awareness. Treatment group B will include a prescribed regimen with use of BITS touch screen technology. Group B participants will receive the same pre- and post- assessment of visual field awareness as Group A participants. The hypothesis is that incorporation of the BITS touch screen technology, being more interactive, will result in better outcomes for visual field awareness. This is an unblinded quasi-randomized control trial that will determine best treatment intervention for visual field impairment. Safety will be measured by the number of reported adverse events. The study period will include 6 sessions per participant, conducted at one site, with the objective of enrolling at least 30 participants to have 15 participants in each study group.

Detailed description

The primary objective of this study is to demonstrate the effectiveness of a multi-session prescribed regimen involving the Bioness Integrated Therapy System (BITS) touch screen technology as a safe, practical, and beneficial means to increase visual field awareness for individuals with neurological vision field deficits receiving inpatient therapy. The overall goal is to determine if the use of BITS touch screen technology more effectively improves visual field awareness than conventional vision interventions involving table-top pen and paper activities. Prior to consenting interested individuals, the presence of a visual field deficit will be confirmed through confrontation testing. Consented participants will perform an initial Bells Test assessment to determine initial visual field awareness. In addition to the Bells Test assessment, a Neuro-Optometrist/investigator will use a Kinetic Field Analyzer to perform a visual field test to measure the density of the field deficit, or blind-spot. Bells Test and Kinetic Field Analyzer testing will be conducted within 1 week of admission to the study (pre-assessment) and within 1 week prior to participant discharge (post-assessment). Consented participants will be alternately assigned to either Group A or Group B. Participants in Group A will be offered traditional vision interventions that will include word search, scanning activities, and saccade training. Participants in Group B will be prescribed and complete a BITS regimen with occupational therapist/investigator using the BITS programs of visual scanning, visual pursuits and/or visual motor. Participants in both groups will complete six, 20 minute, sessions over three-weeks. A convenience sample of 30 participants (15 per group) will be recruited; the enrollment period is expected to last approximately 12 months. In addition to the visual intervention, all participants will be evaluated by the Neuro-Optometrist/investigator for the need of prismatic correction for field expansion therapy. Prismatic correction is customarily used by eye care professionals to correct ocular deviations and align the eyes to correct double vision. This correction uses unequal prismatic correction for each eye. Prismatic correction can also be used in equal powers for each eye that is often called yoked prismatic correction. Yoked prisms are often used with stroke patients since they can change the location of objects in space as well as have the ability to balance visual skews in spatial perception. These patients often present with hemianopic visual field deficits. The yoked prism allows areas that are not seen to be perceived by displacing the objects into the area of vision not blinded by the stroke as well as balancing visual-spatial perceptual impairments. In turn this treatment allows rehabilitative therapy to be more effective with better outcomes and is part of the standard of care. All participants will be evaluated and receive the appropriate prismatic correction as prescribed. Data analysis: All data will be collected and analyzed in an unpaired fashion as appropriate; adjustments for abnormal distribution, unequal variance, and repeated measure will be applied as necessary. In the case of missing or inconsistent data due to early withdraw, early participant discharge, or other unforeseen events, the datasets will be evaluated as normal.

Interventions

OTHERTable Top Visual Intervention

Table top visual interventions and exercises.

DEVICEBioness Integrated Therapy System Visual Intervention

Digital visual interventions and exercises.

Sponsors

Connecticut Community Foundation
CollaboratorUNKNOWN
Gaylord Hospital, Inc
Lead SponsorOTHER

Study design

Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Intervention model description

Participants will be assigned into A and B groups upon admission in alternating fashion. The control group A will be prescribed conventional (table top, pen and paper) vision interventions provided by an occupational therapist and will receive pre- and post- assessment of visual field awareness. Treatment group B will include a prescribed regimen with use of BITS touch screen technology. Group B participants will receive the same pre- and post- assessment of visual field awareness as Group A participants.

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Adults, 18 years or older who are able to provide consent or have Power of Attorney (POA) able to consent. * Must have an acute or subacute (diagnosed within the last 3 months) neurological diagnosis with a visual field deficit as verified by occupational therapist via confrontation testing. * Admitted for inpatient rehabilitation * Demonstrate the ability to follow 1 step directions * Demonstrate sufficient upper extremity strength (as deemed appropriate by occupational therapist) to utilize BITS touch screen technology * Ability to tolerate at least 30 minutes of intervention at a seated wheelchair level.

Exclusion criteria

* Severe cognitive impairments: Unable to follow one step directions, inability to communicate pain, or to stop intervention if needed * Quadriparesis * Previous significant visual impairment impacting visual fields or resulting in legal blindness in past medical history * Re-admitted to Acute Care and do not return within 1 week * Currently on a ventilator for respiratory support * Unstable vital signs or deemed inappropriate to participate in therapy per Medical Staff * Uncontrolled or new (within 24 hours) arrhythmias. * Unresolved or new (within 24 hours) deep vein thrombosis. * Concurrent severe neurological pathology/disease or stroke within 72 hours. * Any reason the physician may deem as harmful to the participant to enroll or continue in the study.

Design outcomes

Primary

MeasureTime frameDescription
Bells TestPre and post tests will be collected within 1 week following enrollment and within 1 week prior to discharge, approximately 1 month from baseline.Used to determine initial visual field awareness. The participant is presented with a standardized pen and paper assessment that includes pictures of bells and other objects. The participant has to locate and circle as many bells as they can without circling any distractors. The participant is scored on the time that it takes to complete the assessment, the number of bells that are located on both the left and right side of the page, and the number of distractors that are located. The Bells test scored on a scale of 0 through 35; the higher the score the better.
Kinetic Field Assessment - Field of ViewPre and post tests will be collected within 1 week following enrollment and within 1 week prior to discharge.Neuro-Optometrist delivered test. Measures the density or presence of field deficits, or blind-spots, in participants using moving objects with a fixed luminance and color. Each participant has both eyes assessed (n = 2). Measured in degrees from 0-360, typical values for healthy adults are 170-200 degrees.
Kinetic Field Testing - Visual Field IndexPre and post tests will be collected within 1 week following enrollment and within 1 week prior to discharge.Neuro-Optometrist delivered test. Measures the density or presence of field deficits, or blind-spots, in participants using moving objects with a fixed luminance and color. Each participant has both eyes assessed (n = 2). Visual Field Index is a percentage from 0-100%, with 100% being a normal field and 0% being a perimetrically blind field.

Countries

United States

Participant flow

Participants by arm

ArmCount
Table Top Visual Intervention
Interventions will include six, 20 minute sessions using pen and paper word search, scanning activities, and saccade visual training. All activities will be conducted with an occupational therapist/investigator. Table Top Visual Intervention: Table top visual interventions and exercises.
16
Bioness Integrated Therapy System Visual Intervention
Intervention will includes six sessions using the Bioness Integrated Therapy System for 20 minutes using the programs of visual scanning, visual pursuits and/or visual motor.All activities will be conducted with an occupational therapist/investigator. Bioness Integrated Therapy System Visual Intervention: Digital visual interventions and exercises.
17
Total33

Baseline characteristics

CharacteristicBioness Integrated Therapy System Visual InterventionTotalTable Top Visual Intervention
Age, Continuous63.4 years
STANDARD_DEVIATION 13.6
63.2 years
STANDARD_DEVIATION 15.9
63.1 years
STANDARD_DEVIATION 18.4
Race (NIH/OMB)
American Indian or Alaska Native
0 Participants0 Participants0 Participants
Race (NIH/OMB)
Asian
3 Participants5 Participants2 Participants
Race (NIH/OMB)
Black or African American
2 Participants4 Participants2 Participants
Race (NIH/OMB)
More than one race
0 Participants0 Participants0 Participants
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
0 Participants0 Participants0 Participants
Race (NIH/OMB)
Unknown or Not Reported
0 Participants0 Participants0 Participants
Race (NIH/OMB)
White
12 Participants24 Participants12 Participants
Sex: Female, Male
Female
8 Participants17 Participants9 Participants
Sex: Female, Male
Male
9 Participants16 Participants7 Participants

Adverse events

Event typeEG000
affected / at risk
EG001
affected / at risk
deaths
Total, all-cause mortality
0 / 160 / 17
other
Total, other adverse events
0 / 160 / 17
serious
Total, serious adverse events
0 / 160 / 17

Outcome results

Primary

Bells Test

Used to determine initial visual field awareness. The participant is presented with a standardized pen and paper assessment that includes pictures of bells and other objects. The participant has to locate and circle as many bells as they can without circling any distractors. The participant is scored on the time that it takes to complete the assessment, the number of bells that are located on both the left and right side of the page, and the number of distractors that are located. The Bells test scored on a scale of 0 through 35; the higher the score the better.

Time frame: Pre and post tests will be collected within 1 week following enrollment and within 1 week prior to discharge, approximately 1 month from baseline.

Population: Number of total items correct

ArmMeasureValue (MEAN)
Pre-Assessment TabletopBells Test14.2 Number of items correct
Post-Assessment TabletopBells Test18.3 Number of items correct
Pre-Assessment BITSBells Test19.3 Number of items correct
Post-Assessment BITSBells Test27.1 Number of items correct
Comparison: Alpha set at 0.05p-value: 0.177995% CI: [-12.6, 2.385]ANOVA
Comparison: Alpha set at 0.05p-value: 0.021995% CI: [-16.3, -1.317]ANOVA
Comparison: Alpha set at 0.05p-value: 0.013995% CI: [-7.24, -0.8849]ANOVA
Comparison: Alpha set at 0.05p-value: <0.000195% CI: [-10.85, -4.682]ANOVA
Primary

Kinetic Field Assessment - Field of View

Neuro-Optometrist delivered test. Measures the density or presence of field deficits, or blind-spots, in participants using moving objects with a fixed luminance and color. Each participant has both eyes assessed (n = 2). Measured in degrees from 0-360, typical values for healthy adults are 170-200 degrees.

Time frame: Pre and post tests will be collected within 1 week following enrollment and within 1 week prior to discharge.

Population: Total Field of View

ArmMeasureValue (MEAN)Dispersion
Pre-Assessment TabletopKinetic Field Assessment - Field of View117.68 DegreesStandard Deviation 43.68
Post-Assessment TabletopKinetic Field Assessment - Field of View167 DegreesStandard Deviation 49.38
Pre-Assessment BITSKinetic Field Assessment - Field of View125.56 DegreesStandard Deviation 44.36
Post-Assessment BITSKinetic Field Assessment - Field of View180.97 DegreesStandard Deviation 34.78
Comparison: Alpha set at 0.05p-value: 0.49395% CI: [-30.59, 14.83]ANOVA
Comparison: Alpha set at 0.05p-value: 0.225595% CI: [-36.68, 8.744]ANOVA
Comparison: Alpha set at 0.05p-value: <0.000195% CI: [-63.18, -35.46]ANOVA
Comparison: Alpha set at 0.05p-value: <0.000195% CI: [-67.66, -43.16]ANOVA
Primary

Kinetic Field Testing - Visual Field Index

Neuro-Optometrist delivered test. Measures the density or presence of field deficits, or blind-spots, in participants using moving objects with a fixed luminance and color. Each participant has both eyes assessed (n = 2). Visual Field Index is a percentage from 0-100%, with 100% being a normal field and 0% being a perimetrically blind field.

Time frame: Pre and post tests will be collected within 1 week following enrollment and within 1 week prior to discharge.

Population: Visual Field Index = \[(Kinetic field measurement) / (normative value)\] \* 100

ArmMeasureValue (MEAN)Dispersion
Pre-Assessment TabletopKinetic Field Testing - Visual Field Index38.96 Visual field indexStandard Deviation 14.46
Post-Assessment TabletopKinetic Field Testing - Visual Field Index55.29 Visual field indexStandard Deviation 16.35
Pre-Assessment BITSKinetic Field Testing - Visual Field Index41.58 Visual field indexStandard Deviation 14.69
Post-Assessment BITSKinetic Field Testing - Visual Field Index59.92 Visual field indexStandard Deviation 11.52
Comparison: Alpha is set at 0.05p-value: 0.4995% CI: [-10.13, 4.909]ANOVA
Comparison: Alpha set at 0.05p-value: 0.224695% CI: [-12.15, 2.886]ANOVA
Comparison: Alpha set at 0.05p-value: <0.000195% CI: [-20.91, -11.74]ANOVA
Comparison: Alpha set at 0.05p-value: <0.000195% CI: [-22.4, -14.29]ANOVA

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026